keyword
https://read.qxmd.com/read/38629251/outcomes-of-the-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-a-population-based-study
#1
JOURNAL ARTICLE
Wenshuai Zheng, Mingjuan Liu, Lixun Guan, Shenyu Wang
BACKGROUND: Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a common complication of follicular lymphoma (FL) and is usually associated with a dismal outcome. However, the survival rate of these patients has improved over the last 20 years with the introduction of rituximab. This study aimed to access the outcome of transformation to DLBCL (t-DLBCL) from FL in a retrospective series that began after the widespread use of rituximab use. In addition, we also compared survival between t-DLBCL and primary DLBCL (p-DLBCL) in the same timeframe...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38627702/mnda-expression-and-its-value-in-differential-diagnosis-of-b-cell-non-hodgkin-lymphomas-a-comprehensive-analysis-of-a-large-series-of-1293-cases
#2
JOURNAL ARTICLE
Li-Fen Zhang, Yan Zhang, Rou-Hong Shui, Hong-Fen Lu, Wen-Hua Jiang, Xu Cai, Xiao-Qiu Li, Bao-Hua Yu
AIMS: MNDA (myeloid nuclear differentiation antigen) has been considered as a potential diagnostic marker for marginal zone lymphoma (MZL), but its utility in distinguishing MZL from other B-cell non-Hodgkin lymphomas (B-NHLs) and its clinicopathologic relevance in diffuse large B-cell lymphoma (DLBCL) are ambiguous. We comprehensively investigated MNDA expression in a large series of B-NHLs and evaluated its diagnostic value. METHODS: MNDA expression in a cohort of 1293 cases of B-NHLs and 338  cases of reactive lymphoid hyperplasia (RLH) was determined using immunohistochemistry and compared among different types of B-NHL...
April 16, 2024: Diagnostic Pathology
https://read.qxmd.com/read/38627366/phase-ii-study-of-novel-orally-pi3k%C3%AE-%C3%AE-inhibitor-tq-b3525-in-relapsed-and-or-refractory-follicular-lymphoma
#3
JOURNAL ARTICLE
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Aibin Liang, Zhiming Li
This registration study assessed clinical outcomes of TQ-B3525, the dual phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular lymphoma (R/R FL). This phase II study (ClinicalTrials.gov NCT04324879. Registered March 27, 2020) comprised run-in stage and stage 2. R/R FL patients after ≥2 lines therapies received oral 20 mg TQ-B3525 once daily in a 28-day cycle until intolerable toxicity or disease progression. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR)...
April 17, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38625832/histopathological-staging-and-differential-diagnosis-of-marginal-zone-lymphoma-of-gastric-mucosa-associated-lymphoid-tissue
#4
JOURNAL ARTICLE
Dong-Feng Ge, Yang-Kun Wang, Shen-Lin Li, Xiong-Fei Zou, Ling-Chao Kong, Wei-Yi Deng, Su-Nan Wang
The purpose of this study was to explore the histopathological staging and differential diagnosis of marginal zone lymphoma in gastric mucosa-associated lymphoid tissue (MALT lymphoma). We performed detailed histomorphology and immunohistochemistry investigations as well as genetic testing on endoscopic biopsy and endoscopic mucosal resection specimens from 18 patients with gastric MALT lymphoma. We found that gastric MALT lymphoma typically begins as a small, isolated area outside the lymphoid follicular mantle zone or proliferates in a multifocal, patchy manner, gradually spreads to the interfollicular zone, forming diffuse proliferation, invades the gastric mucosal glands, and infiltrates or proliferates into the center of peripheral reactive lymphoid follicles...
April 2, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38610963/comparing-r-bendamustine-vs-r-chop-plus-maintenance-therapy-as-first-line-systemic-treatment-in-follicular-lymphoma-a-multicenter-retrospective-geltamo-study
#5
JOURNAL ARTICLE
Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero, Javier López, Paola Villafuerte, Ana Jiménez-Ubieto, Raquel de Oña, Adolfo De la Fuente, Belén Navarro, Javier Peñalver, Pilar Martínez, Carmen Alonso, María Infante, Raúl Córdoba, Blanca Perez-Montero, Jaime Pérez de Oteyza, Sonia González de Villambrosio, Paula Fernández-Caldas, Raquel Del Campo, Daniel García Belmonte, Javier Diaz-Gálvez, Antonio Salar, Juan-Manuel Sancho
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for maintenance therapy notably improves outcomes; however, whether this can be achieved by using the same approach after R-B therapy is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens followed by rituximab maintenance therapy for untreated advanced-stage FL...
March 26, 2024: Cancers
https://read.qxmd.com/read/38608254/two-recurrent-types-of-igh-5-bcl2-breakpoints-representing-cytogenetic-ins-14-18-q32-q21q21-and-t-14-18-q32-q21-mediated-by-the-vdj-and-class-switch-recombination-processes-respectively
#6
JOURNAL ARTICLE
Fumiyo Maekawa, Masahiko Hayashida, Kayo Takeoka, Katsuhiro Fukutsuka, Miho Nakagawa, Takashi Akasaka, Shinichi Sakamoto, Shinji Sumiyoshi, Yoichiro Kobashi, Hitoshi Ohno
We describe two types of IGH :: BCL2 breakpoints involving the 5' region of BCL2 (5' BCL2 ). One was ins(14;18)(q32;q21q21) observed in 2 follicular lymphoma (FL) cases, in which IGH was cleaved at 3' of IGHD and 5' of IGHJ and BCL2 was cleaved at 5' BCL2 and downstream regions, and a 281- or 201-kilobase pair fragment containing the BCL2 protein-coding sequences was invertedly inserted into IGH . In another type observed in 2 FL and 2 chronic lymphocytic leukemia (CLL) cases, breakage and reunion occurred within the switch region associated with IGHM (Sµ) and 5' BCL2 , creating IGH Sµ::5' BCL2 fusion sequences on der(18)t(14;18)(q32;q21)...
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38607394/impact-of-demographics-and-neighborhood-socioeconomic-variables-on-clinical-trial-participation-in-non-hodgkin-lymphoma
#7
JOURNAL ARTICLE
Chijioke Nze, Clark Andersen, Amy Ayers, Jason R Westin, Michael L Wang, Swaminathan P Iyer, Sairah Ahmed, Chelsea C Pinnix, Francisco Vega, Lynne Nguyen, Lorna McNeill, Loretta J Nastoupil, Kehe Zhang, Cici Bauer, Christopher R Flowers
Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with Non-Hodgkin Lymphoma (NHL) seen at MD Anderson Cancer Center (MDACC) to investigate the association between trial participation, race/ethnicity, travel distance and neighborhood socioeconomic status (nSES). Using patient addresses, we ascertained nSES variables on educational attainment, income, poverty, racial composition and housing at the census tract (CT) level...
March 23, 2024: Blood Advances
https://read.qxmd.com/read/38604263/ovarian-tissue-biopsy-for-cryopreservation-by-vaginal-natural-orifice-transluminal-endoscopic-surgery-vnotes-a-new-approach-for-a-minimal-invasive-ovarian-biopsy
#8
JOURNAL ARTICLE
Renato Seracchioli, Manuela Maletta, Enrico Pazzaglia, Antonio Raffone, Rossella Vicenti, Stefano Scarperi, Valentino Bergamini, Diego Raimondo
OBJECTIVE: Vaginal natural orifice transluminal endoscopic surgery (vNOTES) is an emerging surgical procedure that combines the advantages of the vaginal approach with laparoscopic vision and instrumentation [1]. Shorter hospitalization and lower postoperative pain associated to vNOTES [2] may be explained by the advantages of this innovative surgical approach (such as absence of abdominal incisions, shorter operating time, lower insufflation pressure) [2;3]. Ovarian tissue cryopreservation allows to preserve reproductive and endocrine functions in young women with oncological disease at risk of premature ovarian insufficiency (POI) caused by gonadotoxic treatments [4]...
April 9, 2024: Fertility and Sterility
https://read.qxmd.com/read/38601148/clinicopathologic-analysis-of-nodal-t-follicular-helper-cell-lymphomas-a-multicenter-retrospective-study-from-china
#9
MULTICENTER STUDY
Shanshan Ma, Suxiao Li, Xiaona Zuo, Wencai Li, Lifu Wang, Weiping Liu, Zhe Wang, Wei Sang, Yanjie Wang, Xudong Zhang, Mingzhi Zhang
BACKGROUND: Nodal T-follicular helper cell lymphomas (nTFHLs) represent a new family of peripheral T-cell lymphomas (PTCLs), and comparative studies of their constituents are rare. METHODS: This study retrospectively enrolled 10 patients with nTFHL-F and 30 patients with nTFHL-NOS diagnosed between December 2017 and October 2023 at six large comprehensive tertiary hospitals; 188 patients with nTFHL-AI were diagnosed during the same period at the First Affiliated Hospital of Zhengzhou University for comparison...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38600854/patients-with-classic-hodgkin-lymphoma-and-follicular-lymphoma-compared-to-single-malignancy-controls
#10
JOURNAL ARTICLE
Claudiu V Cotta, Shweta Bhavsar, Scott Robertson, James R Cook
Classic Hodgkin lymphoma (CHL) can arise in patients with low-grade B-cell lymphoma. The features of CHL arising in follicular lymphoma (FL) and its outcome are still unclear, mainly due to the very few cases reported. This study compares 17 patients with CHL and FL to 2 control groups: 1 of 26 patients with FL and a second of 60 patients older than 40 when diagnosed with CHL. Of the FL and CHL patients, 8 had simultaneous FL and CHL, while 9 had FL first, followed by CHL 4.7 years later on average. The age at the diagnosis of FL was 61 years for patients with synchronous FL and CHL and of 60 years for FL, followed by CHL at 65 years...
April 11, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38599858/interstitial-pneumonia-associated-with-nodal-t-follicular-helper-cell-lymphoma-a-case-report
#11
JOURNAL ARTICLE
Satoshi Nakamura, Tomotsugu Takano, Kousei Nakatsuru, Kazuya Tsubouchi, Takuji Yamauchi, Mikiko Hashisako, Takeshi Iwasaki, Isamu Okamoto
Nodal T-follicular helper cell lymphoma (nTFHL), a hematologic neoplasm originating from T-follicular helper (TFH) cells, occasionally presents with pulmonary radiographic abnormalities, without neoplastic cellular infiltration. However, the precise mechanisms underlying non-neoplastic pulmonary opacities in patients with nTFHL remain unclear. Previous reports have shown that TFH cell abnormalities are associated with collagen disease and interstitial pneumonia with autoimmune features (IPAF). We herein report a patient with nTFHL accompanied by interstitial pneumonia diagnosed via lung and lymph node biopsies...
April 9, 2024: Internal Medicine
https://read.qxmd.com/read/38595316/analyzing-the-risk-factors-for-disease-progression-within-2%C3%A2-years-and-histological-transformation-in-patients-treated-with-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-as-first-line-treatment-a-15-year-follow-up-of-patients-with-advanced
#12
RANDOMIZED CONTROLLED TRIAL
Takashi Watanabe, Yoshihiro Matsuno, Masashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Kunihiro Tsukasaki, Kensei Tobinai, Hirokazu Nagai
Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38585584/folliculotropic-mycosis-fungoides-associated-with-follicular-mucinosis-a-case-report-and-mini-review
#13
Majed Saleh Aldayhum, Mohammed Saad Alshahrani, Mahmoud Rezk A Hussein, Abdulmajeed Saad Alshahrani, Toka M R Hussein
KEY CLINICAL MESSAGE: F-MF is a rare non-classic variant of MF. In the case of hair loss, this should be a diagnostic consideration. The essence of the diagnosis of F-MF is a careful medical history, physical examination, and a combination of immunohistological and molecular analyses ( Cureus . 2022; 14:e21231, Ann Saudi Med . 2012; 32:283, Oman Med J . 2012; 27:134, Int J Dermatol . 2016; 55:1396, Saudi Med J . 2018; 39:994 and Case Rep Oncol . 2018; 11:436). ABSTRACT: Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma with multiple subtypes...
April 2024: Clinical Case Reports
https://read.qxmd.com/read/38582666/safety-and-toxicity-profiles-of-car-t-cell-therapy-in-non-hodgkin-lymphoma-a-systematic-review-and-meta-analysis
#14
JOURNAL ARTICLE
Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin
BACKGROUND: The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate. METHODS: In this systematic review and meta-analysis, we set out to determine whether there are measurable differences in common toxicities, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), cytopenias, and infections, between CAR T products that are commercially available for the treatment of NHL...
February 15, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38581289/learnings-from-phosphatidylinositol-3-kinase-inhibitors-in-lymphoma-moving-to-a-model-where-less-can-be-more
#15
JOURNAL ARTICLE
Arina Martynchyk, Eliza A Hawkes
The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one-size-fits-all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data. Commentary on: Soumerai et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas...
April 6, 2024: British Journal of Haematology
https://read.qxmd.com/read/38580734/prognostic-value-of-the-combination-of-volume-massiveness-and-fragmentation-parameters-measured-on-baseline-fdg-pet-in-high-burden-follicular-lymphoma
#16
JOURNAL ARTICLE
S Draye-Carbonnier, V Camus, S Becker, D Tonnelet, E Lévêque, A Zduniak, F Jardin, H Tilly, P Vera, P Decazes
The prognostic value of radiomic quantitative features measured on pre-treatment 18 F-FDG PET/CT was investigated in patients with follicular lymphoma (FL). We conducted a retrospective study of 126 FL patients (grade 1-3a) diagnosed between 2006 and 2020. A dozen of PET/CT-derived features were extracted via a software (Oncometer3D) from baseline 18 F-FDG PET/CT images. The receiver operating characteristic (ROC) curve, Kaplan-Meier method and Cox analysis were used to assess the prognostic factors for progression of disease within 24 months (POD24) and progression-free survival at 24 months...
April 5, 2024: Scientific Reports
https://read.qxmd.com/read/38578513/efficacy-and-safety-of-lenalidomide-in-the-treatment-of-b-cell-non-hodgkin-lymphoma
#17
JOURNAL ARTICLE
Yang Liu, Yanju Li, Chike Zhang, Xu Yang, Bo Yang, Jinyang Cheng, Juan Chen, Xiaoshuang Yuan, Ya Li, Ying Chen, Fengqi Zhang, Dongxin Tang, Zhixu He, Feiqing Wang
BACKGROUND: The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an immunomodulatory drug that has shown promising properties and activity in a variety of hematological malignancies. This study evaluated the efficacy and safety of lenalidomide-based regimens in the treatment of B-cell non-Hodgkin lymphoma. METHODS: The PubMed, Science Direct, ClinicalTrials.gov, and Web of Science databases were searched for relevant studies published up to May 2022...
April 5, 2024: Discover. Oncology
https://read.qxmd.com/read/38578156/co-occurrence-of-epstein-barr-virus-positive-nodal-t-nk-cell-lymphoma-and-nodal-t-follicular-helper-cell-lymphoma-of-different-clonal-origins-an-autopsy-case-report
#18
Daisuke Hoshi, Nami Migita, Shin Ishizawa, Yasuharu Sato, Koichi Yamamura, Etsuko Kiyokawa
Nodal T-follicular helper cell lymphoma (TFHL) is a subset of T-cell lymphoma and frequently co-occurs with Epstein-Barr virus (EBV)-positive B-cell lymphoma but not with T/NK-cell lymphoma. Recently, a new entity with a worse prognosis, called EBV-positive nodal T/NK-cell lymphoma (NTNKL) has been established. Here, we report an autopsy case of synchronous multiple lymphomas, including TFHL and NTNKL. The patient was a 78-year-old female admitted with pneumonia. Although pneumonic symptoms were improved, fever, pancytopenia, and disseminated intravascular coagulation emerged, implicating lymphoma...
April 5, 2024: Pathology International
https://read.qxmd.com/read/38571449/progression-free-survival-is-a-weakly-predictive-surrogate-end-point-for-overall-survival-in-follicular-lymphoma-a-systematic-review-and-meta-analysis
#19
JOURNAL ARTICLE
Charles J Milrod, Kang Woo Kim, Christina Raker, Thomas A Ollila, Adam J Olszewski, Ari Pelcovits
Although progression-free survival (PFS) is a commonly used surrogate end-point for clinical trials of follicular lymphoma (FL), no analyses have evaluated the strength of surrogacy for PFS with overall survival (OS). A systematic review was performed and 20 studies (total participants, 10 724) met final inclusion criteria. PFS was weakly associated with OS (correlation coefficient; 0.383, p < 0.001). The coefficient of determination was 0.15 (95% CI: 0.002-0.35) suggesting 15% of OS variance could be explained by changes in PFS...
April 4, 2024: British Journal of Haematology
https://read.qxmd.com/read/38550656/primary-follicular-lymphoma-of-the-prostate-co-existing-with-grade-group-5-prostatic-adenocarcinoma-and-presenting-as-a-pi-rads-lesion-4-on-mpmri
#20
Shubhneet Bal, Oluwole Odujoko, Jacob Fiedler, Steven C Sieber, Edward Beck, Gunjan Gupta
Primary prostatic lymphoma is an exceedingly rare entity comprising less than 0.09% of all prostatic cancers with follicular lymphoma making up only 12% as a subset. To our knowledge, primary follicular lymphoma co-existing with high grade prostatic adenocarcinoma presenting as a PI-RADS lesion 4 on mpMRI has not been previously described. We report the case of a 73-year-old male who presented with mildly elevated PSA and lower urinary tract symptoms. Prostate needle biopsy revealed low grade follicular lymphoma juxtaposed with high grade prostatic adenocarcinoma...
May 2024: Urology Case Reports
keyword
keyword
15642
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.